| Current Price | $0.09 | Mkt Cap | $3.2M |
|---|---|---|---|
| Open | $0.09 | P/E Ratio | -0.18 |
| Prev. Close | $0.09 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.09 - $0.09 | Volume | 3,062,919 |
| 52-Wk Range | $0.08 - $1.05 | Avg. Daily Vol. | 1,846,846 |
| Current Price | $0.09 | Mkt Cap | $3.2M |
|---|---|---|---|
| Open | $0.09 | P/E Ratio | -0.18 |
| Prev. Close | $0.09 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.09 - $0.09 | Volume | 3,062,919 |
| 52-Wk Range | $0.08 - $1.05 | Avg. Daily Vol. | 1,846,846 |
The best Bull and Bear pitches based on recency and number of recommendations.
As of 10/19/11, Neoprobe's New Drug Application (NDA) for Lymphoseek® (tilmanocept) has been accepted for review by the FDA.
Extremely overvalued trash stock.
Read the most recent pitches from players about NAVB.
Recs
BooDog2
(< 20)
Submitted: 5/6/2015 12:12:01 PM :
Start Price:
$1.25
NYSE MKT:NAVB Score:
-193.16
$NAVB basing near the $ once again. New management and great potential with their new platform under Goldberg. Gonzalez as the new CEO pushing the marketing potential for Lymphoseek. $2+ short term potential imo.
Recs
FlyinBlind
(54.39)
Submitted: 3/28/2015 9:32:05 AM :
Start Price:
$1.68
NYSE MKT:NAVB Score:
+196.16
NAVB will outperform the market over the next 5 years, but due to its burn rate on R&D and G&A, it will go through a number of rounds of financing that will dilute out shareholders. This stock will excel, but there are stocks that are closer to monetizing shareholdeer value
Recs
minmartar
(< 20)
Submitted: 9/19/2014 1:00:18 AM :
Start Price:
$1.44
NYSE MKT:NAVB Score:
-200.71
No competition.
Extremely undervalued.
Find the members with the highest scoring picks in NAVB.
Europecv (27.03) Score: +358.99
The Score Leader is the player with the highest score across all their picks in NAVB.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| capostatus | 28.50 | 10/12/2010 |
|
5Y | $1.65 | -94.42% | +259.96% | +354.39 | 0 Comment | |
| stockjock11 | 45.90 | 3/26/2010 |
|
NS | $1.72 | -94.65% | +256.24% | +350.90 | 1 Comment | |
| Europecv | 27.03 | 11/23/2010 |
|
5Y | $1.82 | -94.95% | +252.93% | +347.88 | 0 Comment | |
| Caboverde | 27.05 | 10/22/2010 |
|
5Y | $1.62 | -94.32% | +253.08% | +347.40 | 0 Comment | |
| TheChozen1 | 27.20 | 10/22/2010 |
|
5Y | $1.60 | -94.25% | +252.93% | +347.18 | 0 Comment | |
| SuperNova007 | 99.12 | 4/9/2010 |
|
5Y | $1.79 | -94.86% | +250.65% | +345.51 | 0 Comment | |
| BuffettJunior1 | 98.79 | 10/17/2011 |
|
5Y | $3.02 | -96.95% | +244.68% | +341.63 | 1 Comment | |
| walt393 | 99.87 | 12/15/2011 |
|
5Y | $2.46 | -96.26% | +239.22% | +335.48 | 0 Comment | |
| williamstep | 98.00 | 6/3/2011 |
|
5Y | $4.70 | -98.04% | +220.66% | +318.70 | 0 Comment | |
| jrokket731 | 56.82 | 2/25/2011 |
|
5Y | $4.60 | -98.00% | +215.93% | +313.93 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
